<--- Back to Details
First PageDocument Content
Medicine / Acute intermittent porphyria / Hereditary coproporphyria / Variegate porphyria / Erythropoietic protoporphyria / Erythropoietic porphyria / Porphyrin / Gunther disease / Porphobilinogen deaminase / Porphyrias / Health / Chemistry
Date: 2014-02-26 18:32:33
Medicine
Acute intermittent porphyria
Hereditary coproporphyria
Variegate porphyria
Erythropoietic protoporphyria
Erythropoietic porphyria
Porphyrin
Gunther disease
Porphobilinogen deaminase
Porphyrias
Health
Chemistry

2nd Quarter, 2006 Protect Our Future Physician Chosen 1st International Patient Meeting

Add to Reading List

Source URL: www.porphyriafoundation.com

Download Document from Source Website

File Size: 420,15 KB

Share Document on Facebook

Similar Documents

Porphyria (Cutaneous) Testing Algorithm* Symptom: Skin manifestations restricted to sun-exposed areas Possible cutaneous porphyria: ■ Porphyria cutanea tarda (PCT) ■ Erythropoietic protoporphyria (EPP)

Porphyria (Cutaneous) Testing Algorithm* Symptom: Skin manifestations restricted to sun-exposed areas Possible cutaneous porphyria: ■ Porphyria cutanea tarda (PCT) ■ Erythropoietic protoporphyria (EPP)

DocID: S7Ie - View Document

First Report on NICD MLU activities in Sierra Leone, Freetown[removed]August 2014 Prepared by: Dr Petrus Jansen van Vuren, Ms Chantel Le Roux, Mr Günther Meier and Prof. Janusz T. Paweska  The mobilization and coordinatio

First Report on NICD MLU activities in Sierra Leone, Freetown[removed]August 2014 Prepared by: Dr Petrus Jansen van Vuren, Ms Chantel Le Roux, Mr Günther Meier and Prof. Janusz T. Paweska The mobilization and coordinatio

DocID: PQ40 - View Document

GUNTHER FABER WTO/WHO PRESENTATION: OSLO, 9 APRIL 2001 GlaxoSmithKline is determined to play its full part in improving access to medicines for the world’s poorest people. The company is acutely aware of the unacceptab

GUNTHER FABER WTO/WHO PRESENTATION: OSLO, 9 APRIL 2001 GlaxoSmithKline is determined to play its full part in improving access to medicines for the world’s poorest people. The company is acutely aware of the unacceptab

DocID: PPaJ - View Document

Pharmaceutical industry / GlaxoSmithKline / HIV / Zidovudine / AIDS / Antiretroviral drug / Neglected tropical disease research and development / Campaign for Access to Essential Medicines / Health / Medicine / HIV/AIDS

GUNTHER FABER WTO/WHO PRESENTATION: OSLO, 9 APRIL 2001

DocID: PIae - View Document

THE NICD/NHLS EBOLA MOBILE DIAGNOSTIC LABORATORY IN SIERRA LEONE ON THE FRONTLINE OF THE WAR AGAINST EBOLA CRISIS (NICD MLU SECOND REPORT) Report by: Prof. Janusz T. Paweska, Ms Chantel Le Roux, Mr Günther Meier, Dr Pet

THE NICD/NHLS EBOLA MOBILE DIAGNOSTIC LABORATORY IN SIERRA LEONE ON THE FRONTLINE OF THE WAR AGAINST EBOLA CRISIS (NICD MLU SECOND REPORT) Report by: Prof. Janusz T. Paweska, Ms Chantel Le Roux, Mr Günther Meier, Dr Pet

DocID: HH21 - View Document